SVMPharma Real World Evidence – Real World Evidence as a driver of HTA approv...SVMPharma Limited
SVMPharma Real World Evidence (RWE) – In this article we examine the benefits of RWE in support of HTA submissions and re-submissions, and ask whether RWE is something you can afford to pass up. For more resources RWE visit us at svmpharma.com
Real world data is no longer just for those trained in health economics and outcomes research — it can and will touch everyone in the pharma/healthcare space.
CBI asked industry's foremost RWD thought leaders a variety of questions to better understand how bio/pharmaceutical teams can collaborate and capture data in an aggregated form to continue to improve the value of products in development with real world, real-time data.
Netta Hollings (Programme Manager - Mental Health and Community Care) discusses how you can get the most out of the Maternity Services Data Set (MSDS) and the Child Health Data Sets.
The data sets provide comparative, mother and child-centric data that will be used to improve clinical quality and service efficiency; and to commission services in a way that improves health and reduce inequalities.
SVMPharma Real World Evidence – Real World Evidence as a driver of HTA approv...SVMPharma Limited
SVMPharma Real World Evidence (RWE) – In this article we examine the benefits of RWE in support of HTA submissions and re-submissions, and ask whether RWE is something you can afford to pass up. For more resources RWE visit us at svmpharma.com
Real world data is no longer just for those trained in health economics and outcomes research — it can and will touch everyone in the pharma/healthcare space.
CBI asked industry's foremost RWD thought leaders a variety of questions to better understand how bio/pharmaceutical teams can collaborate and capture data in an aggregated form to continue to improve the value of products in development with real world, real-time data.
Netta Hollings (Programme Manager - Mental Health and Community Care) discusses how you can get the most out of the Maternity Services Data Set (MSDS) and the Child Health Data Sets.
The data sets provide comparative, mother and child-centric data that will be used to improve clinical quality and service efficiency; and to commission services in a way that improves health and reduce inequalities.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
Edifecs: Demonstrating who you are in CJREdifecs Inc
A hands-on approaches for hospitals to strategically align orthopedic surgeons and post-acute providers under CJR. This Presentation focuses on tools that providers can use to help manage their performance to be successful under the new value-based environment.
COVID-19 Capacity Planning Tool Demo: New Infection Forecasting with Empirica...Health Catalyst
Last month we introduced our public Capacity Planning Tool to support your ongoing COVID-19 response and recovery. We have introduced a major update allowing you to forecast infections based upon actual county level data and dynamic infection spread rates (Empirical Model), as well as better classification of ICU patients.
You can still run multiple scenarios and estimate demand for beds, mechanical ventilators, supplies such as personal protection equipment (PPE), and staff. We hope that you will view this demo as our experts explain how to best use these new features and answer questions from the audience.
The topics covered include:
- A brief review of the Capacity Planning Tool
- How to forecast infections based upon actual county level data and dynamic infection spread rates
- Improved classification of ICU patients
- Where to get additional help if needed
- Q&A session with our experts
N-QI-CAN brings together the regional clinical audit / effectiveness networks from across England. There are 14 regional clinical audit/effectiveness networks all of whom have representatives regularly attending NQICAN meetings. Wales and Northern Ireland are also represented on the group to enable sharing of good practice and collaborative working.
NQICAN has several 'stakeholder members' including NHS England, HQIP and NICE. Several of the Royal Colleges and other key stakeholders are represented.
This is the NQICAN annual report for 2016.
Lisa Annaly, Head of Provider Analytics at the Care Quality Commission, discusses lessons learned from the CQC as they have worked to monitor care quality over time.
An Alternative Clinical Research Activity League Table for Acute NHS Trusts a...Paul Roberts
Session 3.6 at the Annual NHS R&D Forum Conference
(Tuesday 16th May 2017, Hilton Manchester Deansgate)
Presentation Delivered by Paul Roberts
For copies of the full actual league tables please contact paul.roberts2@meht.nhs.uk
Integrate RWE into clinical developmentIMSHealthRWES
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the author’s experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
Edifecs: Demonstrating who you are in CJREdifecs Inc
A hands-on approaches for hospitals to strategically align orthopedic surgeons and post-acute providers under CJR. This Presentation focuses on tools that providers can use to help manage their performance to be successful under the new value-based environment.
COVID-19 Capacity Planning Tool Demo: New Infection Forecasting with Empirica...Health Catalyst
Last month we introduced our public Capacity Planning Tool to support your ongoing COVID-19 response and recovery. We have introduced a major update allowing you to forecast infections based upon actual county level data and dynamic infection spread rates (Empirical Model), as well as better classification of ICU patients.
You can still run multiple scenarios and estimate demand for beds, mechanical ventilators, supplies such as personal protection equipment (PPE), and staff. We hope that you will view this demo as our experts explain how to best use these new features and answer questions from the audience.
The topics covered include:
- A brief review of the Capacity Planning Tool
- How to forecast infections based upon actual county level data and dynamic infection spread rates
- Improved classification of ICU patients
- Where to get additional help if needed
- Q&A session with our experts
N-QI-CAN brings together the regional clinical audit / effectiveness networks from across England. There are 14 regional clinical audit/effectiveness networks all of whom have representatives regularly attending NQICAN meetings. Wales and Northern Ireland are also represented on the group to enable sharing of good practice and collaborative working.
NQICAN has several 'stakeholder members' including NHS England, HQIP and NICE. Several of the Royal Colleges and other key stakeholders are represented.
This is the NQICAN annual report for 2016.
Lisa Annaly, Head of Provider Analytics at the Care Quality Commission, discusses lessons learned from the CQC as they have worked to monitor care quality over time.
An Alternative Clinical Research Activity League Table for Acute NHS Trusts a...Paul Roberts
Session 3.6 at the Annual NHS R&D Forum Conference
(Tuesday 16th May 2017, Hilton Manchester Deansgate)
Presentation Delivered by Paul Roberts
For copies of the full actual league tables please contact paul.roberts2@meht.nhs.uk
Integrate RWE into clinical developmentIMSHealthRWES
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the author’s experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.
The ability to provide safe, urgent and integrated care is fundamental to the future
delivery of the health and social care system. We need information to follow the
patient along their pathway, so clinicians and patients can have access to the right
information at the right time. In addition, commissioners need to be able to link patient information across multiple settings to improve the services provided to their population. This needs an underpinning primary identifier across the system - the NHS Number (NHSN)
What's Next: What's Next: Healthcare Marketing Cloud ft. TriplOgilvy Consulting
We are living in the age of data and the promise for marketers is the ability to harness this potential to become smarter about our customers. The opportunity is also the challenge, with so much data, how can we decipher what is useful and valuable to our customers?
GDPR and HIPPA have redefined the approach Healthcare companies use to manage data for marketing, in this webinar learn how Ogilvy has created a proprietary data set dubbed Tripl that, combined with our data consultancy, enables the use of data to intelligently market to HCP’s.
From the Nexus project showcase. Presented by Dr Martin Wilson, Clinical Leader I.T., Pegasus Health and Symon McHerron, CIO, Pegasus Health at HINZ 2014, 11 November 2014, 1.45pm, Plenary Room
Richard Corbridge, the dynamic and innovative CIO for the NIHR Clinical Research Network, has brought significant and successful business change across health and clinical research.
He has strong beliefs that technology and
information can have a significant positive impact on the way healthcare is delivered.
Richard will be reaching for his crystal ball and talking about service management in 2030!
TECHNOLOGY and INFORMATION are now more than
ever ingrained in all that is done throughout the world and
we must adopt all elements of them or risk falling behind the
KNOWLEDGE curve.
Clinical Research Network – January 2013
- Approximately 55 different systems in place
- Around 35 different ways of collating reports
- 16 different topic-wide databases
- Significant bespoke reporting
- Data debate
-System based and system led change
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
The EDGE 2014 User Conference
1. Supporting research to make patients, and the NHS, better
Supporting the implementation of LPMS for the
good of research information...
A National Perspective
Richard Corbridge, CIO
2. …for the good of research
information...
“As part of the National Institute for Health Research, we ensure that
the NHS can provide the infrastructure that allows high-quality clinical
research to take place within the NHS, so that patients can benefit from
new and better treatments”
Our key roles are:
To enable the provision of research
To performance manage where provision has been provided
To provide information about research capability
To facilitate the sharing of best practice for delivery
5. Measure:
Number
of
par,cipants
recruited
in
a
repor,ng
quarter
into
NIHR
CRN
Por:olio
studies
Calcula,on:
Recruitment
(both
commercial
and
non-‐
commercial)
by
quarter,
mapped
to
an
English
site
100,398
174,820
149,196
112,233
125,410 159,963
126,949
124,668
152,583114,558
139,800
133,798
0
100,000
200,000
300,000
400,000
500,000
600,000
700,000
2009/10 2010/11 2011/12
Participants
Q1 Q2 Q3 Q4 Financial Year Target
6. Measure:
HLO
2:
Propor,on
of
contract
studies
achieving
or
surpassing
their
recruitment
target
during
their
planned
recruitment
period,
at
confirmed
Network
sites
Calcula,on:
Part
1:
(Actual
Closure
Date-‐Actual
Opening
Date)/(Planned
Closure
Date
-‐
Actual
Opening
Date)
Part
2:
(Recruitment
total
at
network
sites
/
Planned
Network
Sample
Size)
Studies
have
to
meet
Part
1
&
Part
2
to
count
toward
objec,ve.
Therefore
≤
100%
to
,me
AND
≥
100%
to
target
Closed
studies
only:
Actual
Closure
Date
will
determine
repor,ng
period
Por:olio
Entry
Date
&
Actual
Opening
Date
(from
April
1st
2010)
will
determine
which
studies
are
included
1
4 5
6
15
14
19
54
0
1
7
11 19
13
13
25
16 67
0%
50%
100%
Q1 Q2 Q3 Q4 Annual
Total
Q1 Q2 Q3 Q4 Annual
Total
2010/11 2011/12PercentageofStudies
Studies failing to achieve their recruitment target during their planned
recruitment period
Studies achieving or surpassing their recruitment target during their planned
recruitment period
7. Measure:
Number
of
commercial
contract
studies
on
the
NIHR
CRN
Por:olio
as
a
percentage
of
the
total
commercial
MHRA
CTA
approvals
for
Phase
II–IV
studies,
on
an
annual
basis
Calcula,on:
No.
of
studies
adopted
on
to
the
CRN
Por:olio
No.
of
Industry
studies
approved
by
MHRA
per
financial
year
63
55
71 74
263 71
84
60
98
313
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q1 Q2 Q3 Q4 Annual
Total
Q1 Q2 Q3 Q4 Annual
Total
2010/11 2011/12
PercentageofStudies
% NIHR CRN adopted studies as a proportion of MHRA CTA
approvals
Interim Target
Final Target
8. Measure:
Propor,on
of
studies
obtaining
NHS
permission
within
40
calendar
days
(from
receipt
of
a
valid
complete
applica,on)
9 12
19
14 54
37
60
47 69 213
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Q1 Q2 Q3 Q4 Annual
Total
Q1 Q2 Q3 Q4 Annual
Total
2010/11 2011/12
PercentageofStudies
% Studies Achieving NHS Permission Within 40 Days
Interim Target
Final Target
9. Measure:
HLO
5:
Propor,on
of
contract
studies
achieving
first
par,cipant
recruited
within
30
calendar
days
of
NHS
Permission
being
issued
or
First
Network
Site
Ini,a,on
Visit,
at
confirmed
Network
sites
Calcula,on:
Date
of
First
Network
Par,cipant
First
Visit
(
FNPFV)
-‐
(Date
of
first
NHS
Permission
at
network
site
OR
First
Network
Site
Ini,a,on
Visit,
whichever
is
later)
3 9
12
8
32
29
20
25
30
104
4
7
5
16
8
12
9
3
32
1 5
8
14 8 9 10 8 35
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q1 Q2 Q3 Q4 Annual
Total
Q1 Q2 Q3 Q4 Annual
Total
2010/11 2011/12
PercentageofStudies
30 Days or Less Between 31 and 60 Days
More than 60 Days Interim Target
Final Target
10. Measure:
HLO
6:
Propor,on
of
NHS
Trusts
recrui,ng
each
year
into
NIHR
CRN
Por:olio
studies
Calcula,on:
The
propor,on
of
trusts
on
the
CCRN
team's
list
of
member
organisa,ons
that
are
repor,ng
recruitment
at
any
point
in
the
previous
rolling
year.
For
example
the
metric
in
Q3
2011/12
will
examine
whether
there
has
been
recruitment
a]ributed
to
that
trust
at
any
point
in
Q4
2010/11,
Q1
2011/12,
Q2
2011/12
or
Q3
2011/12.
90%
91%
92%
93%
94%
95%
96%
97%
98%
99%
100%
Q1 Q2 Q3 Q4 Annual
Total
Q1 Q2 Q3 Q4 Annual
Total
2010/11 2011/12
PercentageofNHSTrusts
Percentage of Trust Participating in Studies
Interim Target
Final Target
12. NIHR Clinical Research Network
Supporting the implementation of LPMS for the good of research
information…
Although the Clinical Research Network operates as one organisation,
we are made up of a number of different parts:
• Six “Topic” Research Networks (covering Cancer, Dementia and
Neurodegenerative Diseases, Diabetes, Medicines for Children,
Mental Health and Stroke)
• A Primary Care Research Network to support research in this part of
the health service
• A Comprehensive Clinical Research Network, which covers all other
disease areas
13. dfd CPMS Context diagram
CPMS
IRAS
CRN Finance Tool
Local Portfolio
Management
Systems
Commercial
CTMS
Other NHS
Organisation Systems
CSP RDMIS
Module/ LRR
NIHR Coordinating
Centre MIS
Requirements for interfacing not
currently known.
Requirements for interfacing not
currently known.
CCT
Requirements for interfacing not
currently known.
Feasibility Tool
Study and Site Data
Study and Site Data
Study Related Data
Research Activity Data
Research Activity Data
Study and Organisation
DataStudy Related Data
Study Related Data
ISRCTN Number
Study Related Data
Study Related Data
Study Related Data
Study and Organisation
Data
Initial Study Data
ISRCTN Registration
Request and Study Data
Data Form Submissions
Site Activity and Performance Data
14. Version
2.0
Strategic
Alignment
and
Change
Modular
design
ODS
Codes
ODS
codes
HEFCE
codes
Contact
Mgmt
Service
layer
Hierarchies
Index
tables
Indexed
tables
Lookups
Tasks
by
role
“to
do”
panes
Monitor
progress
Structured
legacy
data
Sta,s,cs
package
Forecasts
Trend
analysis
Scheduled
data
cuts
Data
backups
Guaranteed
Up
,me
Planned
down
,me
Fast
Performance
Scheduled
changes
and
releases
NHS
reform
Future
proofing
Version
2.0
Commercial
delivery
15. Central Portfolio Management
System (CPMS)
What stage is it in?
Procurement activity continues on target to identify and select a preferred
supplier for the CPMS development. The programme team continue to refine
the requirements specification at pace to meet the delivery timelines.
CPMS will provide the NIHR CRN with a national information system to:
a. Capture high quality study information
b. Capture data on participant recruitment anywhere and everywhere in the
health research environment
c. Enable sophisticated reporting to support performance management and
delivery of the Networks
Programme
Planning
Requirements
gathering and
Procurement
Initiation
Procurement
– Contract
Award
Design
and Build
Train and
Deploy
Programme
Close
We are here
16. NIHR Clinical Research Network
More than simply performance management and metrics…
• Open Data Platform
• Coordinated System for NHS Permissions(CSP)
• Feasibility Tool
• Reference Data Gateway
• Interim Industry Tracker (IIT)
• Industry Costing Template
• UK Clinical Trials Gateway
• Industry Support Systems (SIP)
19. Reference Data Gateway
Gateway Project Pilot – Context Diagram
NIHR
Client System
NIHR
Client System
NIHR
Client System
CfH
Organisation Data Service
(ODS)
Reference Data
Gateway
Reference
Database
NHS Organisation
Change plans
Updates to NHS
Organisation Structure
Administrative updates
to NHS-NIHR
relationships
Ad hoc queries
and responses
Requests for
new entries
4.2
4.5
4.4
4.1
4.3
Reference Data Gateway
includes communications
and interfaces to all parties
CRNCC Information Management
Team (IM)
Service
Requests
Reference Data
Gateway Service
Service
Requests
Service
Requests